Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
More Reading from MarketBeat.com
Top 5 Insider Buys From Q1: Buy, Sell, or Hold in Q2?Submitted by Thomas Hughes. Article Posted: 4/6/2026. 
Key Points
- Insiders were active in Q1, but insider buying isn't enough to warrant an investor buy; diligence is due.
- Institutional and analyst trends are better indicators of a stock's price direction.
- Each stock on this list has a catalyst to drive it higher, and risks to offset the opportunity.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
Insiders were buying stock in Q1 2026, signaling conviction in their businesses and full-year outlooks. For investors, whether to buy, sell, or hold in Q2 depends on broader market forces and how each stock fits into a portfolio. E.W. Scripps: Most Bought by Insiders in Q1 2026E.W. Scripps (NASDAQ: SSP) saw the most insider buying in Q1. InsiderTrades tracked 34 purchases by 16 insiders, including multiple family members. That concerted activity reflects confidence in a multiyear turnaround aimed at 2028 EBITDA growth. Management is intensifying its focus on streaming and reshaping the portfolio—divesting underperforming assets and adding higher-performing media properties—to improve revenue coverage and cost metrics.
The mainstream explanation for the Iran airstrikes may not be the full story. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there's a deeper motive behind the bombing campaign that most coverage is ignoring.
If you're making investment decisions based on what you're hearing in the news, Wiggin argues you could be working with an incomplete picture. Read Addison Wiggin's full breakdown of the real Iran story
Institutions also support the stock, owning nearly 70% and adding to positions in Q1. Analysts remain cautious: coverage has increased but rating revisions are mixed and consensus sentiment is "Reduce." However, price targets are generally robust, and even the low end implies upside. Catalysts this year include mid-cycle election advertising, margin improvement, cash flow gains, and debt reduction. 
W.R. Berkley Is Getting Accumulated in 2026W.R. Berkley (NYSE: WRB) showed significant activity in Q1, with InsiderTrades reporting 37 acquisitions attributed to insiders. Much of that activity stems from a single major shareholder—Sumitomo Insurance Company of Japan—which made multiple purchases. Sumitomo, a global property insurer, appears intent on expanding its U.S. footprint and aims to own roughly 15% of WRB. Including Q1 purchases, insiders now own about 25% of the stock. Institutional investors also back WRB, owning nearly 70% (including Sumitomo) and acting as net buyers in Q1—purchasing at roughly a $4-to-$1 ratio versus sellers. That accumulation provides support and helps limit downside risk. Analysts are more cautious (consensus: Hold), but coverage is ample and upside potential remains. 
Service Property Trust Insiders Buy in Bulk Service Property Trust (NASDAQ: SVC) ranked highly by share volume. Three insiders bought nearly 42 million shares—primarily director Adam D. Portnoy—raising insiders' stake to about 1.5%. While small relative to total shares outstanding, the purchases signal confidence in the company's value in 2026. SVC is a triple-net REIT focused on service stations and hotels, operating a portfolio of branded properties. Institutional investors own roughly 84% of the stock and were net buyers in Q1. Many analysts rate it a Hold but imply nearly 50% upside. Catalysts this year include restructuring, asset sales, and debt reduction. Improving travel demand could also lift performance as the year progresses. 
Insider Puts Bottom in Coupang StockCoupang (NYSE: CPNG), the South Korean e-commerce company, saw a single insider acquire shares in three transactions. That buying helped establish a near-term market bottom, but early-April technicals remain unfavorable. The stock could continue to drift lower and potentially reach the low teens by mid-year. The primary overhang is a data breach affecting millions—roughly half of South Korea's population—and the uncertain impact on business and customer trust. Institutional investors own about 85% of the stock and have been net buyers for more than six consecutive quarters, increasing activity into Q1 2026. Analyst trends skew favorable: 11 rate it Hold, with a consensus implying roughly 40% upside. Potential catalysts include international expansion, AI-driven efficiency improvements, and recovery efforts following the breach. 
Korro Bio Broad-Based Purchases and Sell-Side SupportKorro Bio (NASDAQ: KRRO) stands out for broad insider support. InsiderTrades shows purchases by more than a dozen insiders and major shareholders in Q1, bringing insider ownership to roughly 4.6%. Institutional holdings are modest (about 13% as of early April) but appear to be accumulating. Analysts are bullish: 11 provide a consensus Moderate Buy and imply roughly 150% upside. Catalysts include advancement of gene-editing therapies following a major restructuring. The company reports sufficient liquidity through 2028 but must commercialize its technology by then. Upcoming potential catalysts include regulatory filings and clinical testing programs for candidate therapies. 
|
Post a Comment
Post a Comment